Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation-Reference-Cited by-同舟云学术

Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation

Published:2014-05-12 Issue:7 Volume:49 Page:895-901
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Tischer J,Engel N,Fritsch S,Prevalsek D,Hubmann M,Schulz C,Zoellner A K,Bücklein V,Lippl S,Reibke R,Rieger C T,Ledderose G,Stemmler H J,Hiddemann W,Schmid C,Hausmann A

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201483.pdf

Reference45 articles.

1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

2. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012; 119: 1599–1606.

3. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/-Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115: 622–629.

4. Schmid C, Schleuning M, Aschan J, Ringden O, Hahn J, Holler E et al. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004; 18: 1430–1433.

5. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229–1235.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients;Blood Cancer Journal;2024-05-02

2. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia - an EBMT registry analysis of 1540 patients;2024-03-05

3. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy;Molecular Cancer;2023-11-11

4. Second Allogeneic Stem Cell Transplantation in Acute Leukemia with Post-Transplantation Relapse;Medical Records;2023-09-18

5. Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia;Bone Marrow Transplantation;2023-09-15